Drug Interactions between Osteo Bi-Flex Joint Health and Vitamin D3

MONITOR: Additive effects and possible toxicity (e.g., hypercalcemia, hypercalciuria, and/or hyperphosphatemia) may occur when patients using vitamin D and/or vitamin D analogs ingest a diet high in vitamin D, calcium, and/or phosphorus. The biologically active forms of vitamin D stimulate intestinal absorption of calcium and phosphorus. This may be helpful in patients with hypocalcemia and/or hypophosphatemia. However, sudden increases in calcium or phosphorus consumption due to dietary changes could precipitate hypercalcemia and/or hyperphosphatemia. Patients with certain disease states, such as impaired renal function, may be more susceptible to toxic side effects like ectopic calcification. On the other hand, if dietary calcium is inadequate for the body's needs, the active form of vitamin D will stimulate osteoclasts to pull calcium from the bones. This may be detrimental in a patient with reduced bone density.

MANAGEMENT: Given the narrow therapeutic index of vitamin D and vitamin D analogs, the amounts of calcium, phosphorus, and vitamin D present in the patient's diet may need to be taken into consideration. Specific dietary guidance should be discussed with the patient and regular lab work should be monitored as indicated. Calcium, phosphorus, and vitamin D levels should be kept within the desired ranges, which may differ depending on the patient's condition. Patients should also be counseled on the signs and symptoms of hypervitaminosis D, hypercalcemia, and/or hyperphosphatemia.

Systemic exposure of boswellic acid extracts from boswellia serrata are variable and may be affected by administration with food. The mechanism for the interaction with food has not been fully established. One study of 12 subjects demonstrated that 786 mg of oral Boswellia serrata gum resin extract administered with a high-fat meal resulted in a prolonged AUC and Cmax of acetyl-11-keto-beta-boswellic acid (AKBA) (AUC 414%; Cmax 380%) and 11-keto-?-boswellic acid (KBA) (AUC 272%; Cmax 171%) compared to dose administration in a fasted state. In a different study, 800 mg of oral Boswellia serrata gum resin extract administered to 12 subjects exhibited a 1.4-fold increase in KBA AUC when administered with food compared to administration in a fasted state, without a difference in Cmax. No difference in AKBA pharmacokinetics was observed. The clinical significance of the administration of boswellia with food is unknown.

The recommended maximum number of medicines in the 'vitamin d analogs' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'vitamin d analogs' category:

• Osteo Bi-Flex Joint Health (boswellia/cholecalciferol/glucosamine)
• Vitamin D3 (cholecalciferol)

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.